Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease

2022/01/01 by Hilary Grosso Jasutkar, Stephanie E. Oh, Stephanie Oh +1 · 2 citations
Medicine · Neuroscience · #Parkinson's Disease Mechanisms and Treatments #Nuclear Receptors and Signaling #Neurological disorders and treatments

paper · pdf · doi:10.1124/pharmrev.120.000133

Citations

• α-Synuclein in Lewy bodies
• α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy?
• α-Synuclein impairs macroautophagy: implications for Parkinson’s disease
• Parkin is recruited selectively to impaired mitochondria and promotes their autophagy
• α-Synuclein Is Degraded by Both Autophagy and the Proteasome
• MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Cited by

• Randomized Phase I Trial of the α‐Synuclein Antibody Lu AF82422
• Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation